Table 3

Sugar-sweetened beverage consumption and change in gout risk, with stratification by SLC2A9 genotype

		Obs	Δ In gout risk, 95% CI (odds ratio)*	p	β_Interaction (95% CI)†	p
NZ European Caucasian	Unstratified	563	1.20 (1.03 to to 1.40)	0.020	0.021 (−0.016 to 0.058)	0.27
	C allele non-carrier	373	1.16 (0.95 to 1.43)	0.14
	C allele carrier	148	1.27 (0.96 to 1.67)	0.091
NZ Ma¯ori	Unstratified	463	1.11 (0.98 to 1.27)	0.11	−0.064 (−0.12 to −0.011)	0.018
	C allele non-carrier	396	1.19 (1.03 to 1.37)	0.019
	C allele carrier	51	0.76 (0.49 to 1.16)	0.20
NZ Pacific Islander	Unstratified	489	1.13 (1.01 to 1.27)	0.030	0.073 (−0.018 to 0.16)	0.12
	C allele non-carrier	454	1.11 (0.99 to 1.25)	0.039
	C allele carrier	27	1.71 (0.85 to 3.42)	0.13
ARIC	Unstratified	6721	1.09 (0.94 to 1.27)	0.26	0.00028 (−0.0067 to 0.0072)	0.94
	G allele non-carrier‡	4082	1.05 (0.88 to 1.26)	0.58
	G allele carrier	2639	1.16 (0.88 to 1.54)	0.29
All Populations Combined	Unstratified	8236	1.13 (1.06 to 1.20)	1.9×10⁻⁴	−0.013^§ (−0.022 to −0.003)	0.010
	Minor allele non-carrier‡	5305	1.12 (1.05 to 1.21)	0.001
	C allele carrier	2888	1.15 (0.98 to 1.34)	0.082

*Change in gout risk per increase in consumption category adjusted by age, sex, BMI, alcohol (continuous variable), fruit intake (continuous variable), kidney disease, high blood pressure, relatedness and sample set where combined.
†SSB/day ordinal (ordered) variables (0, 1, 2, 3, 4, 5, 6) were created as described in the supplementary material and used as a continuous variable to derive the SSB by genotype interaction term with risk of gout as outcome.
‡ARIC genotyped with rs11942223 surrogate rs6449173 (major allele A, minor allele C).
§Interaction term by Mantel Haenszel meta-analysis was 0.000 (−0.033 to 0.034), p=0.99 (the p value of the Q test for heterogeneity was 0.025).
ARIC, Atherosclerosis Risk in Communities; NZ, New Zealand; Obs, Observations; SSB, sugar (sucrose)-sweetened beverage.